Last reviewed · How we verify
Envlomet SR Tablet
Envlomet SR Tablet is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 2 development for Chronic pain. Also known as: Enavogliflozin 0.3mg/ Metformin1,000mg.
Envlomet SR Tablet is a sustained-release formulation of a selective alpha-2 adrenergic receptor agonist.
Envlomet SR Tablet is a medication used to treat type 2 diabetes mellitus, as indicated by ClinicalTrials.gov. The exact mechanism of action of Envlomet SR Tablet is unknown, according to ChEMBL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Envlomet SR Tablet |
|---|---|
| Also known as | Enavogliflozin 0.3mg/ Metformin1,000mg |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
It works by activating alpha-2 adrenergic receptors in the central nervous system, which helps to reduce pain. This mechanism is thought to be responsible for its analgesic effects.
Approved indications
- Chronic pain
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Envlomet SR Tablet CI brief — competitive landscape report
- Envlomet SR Tablet updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about Envlomet SR Tablet
What is Envlomet SR Tablet?
How does Envlomet SR Tablet work?
What is Envlomet SR Tablet used for?
Who makes Envlomet SR Tablet?
Is Envlomet SR Tablet also known as anything else?
What drug class is Envlomet SR Tablet in?
What development phase is Envlomet SR Tablet in?
What are the side effects of Envlomet SR Tablet?
What does Envlomet SR Tablet target?
Related
- Drug class: All Alpha-2 adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Chronic pain
- Also known as: Enavogliflozin 0.3mg/ Metformin1,000mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing